Abstract
Graft-versus-host disease (GvHD) caused by alloreactive T cells within the graft is a major drawback of allogeneic BMT, but depletion of T cells leads to higher rates of relapse, opportunistic infections and graft failure. Therefore, selective removal of GvHD-inducing alloreactive T cells might be beneficial. We describe here the separation of alloresponsive T cells, based on carboxyfluorescein succimidyl ester labeling, in vitro allostimulation and FACS-sorting. In vivo effects of the separated cell populations were investigated in the context of allogeneic BMT in murine models: in vitro resting T cells were shown to survive in the allogeneic host and retain immunoreactivity against ‘third-party’ antigens. As demonstrated in two different transplantation models, elimination of proliferating cells significantly reduces GvHD but offers no advantages to using T-cell-depleted bone marrow alone concerning engraftment and tumor control. Transplanting T cells that proliferate in response to tumor antigens in vitro may narrow down the spectrum of antigens recognized by T cells and therefore reduce GvHD while maintaining graft-facilitating function and tumor control. Therefore, selecting tumor-reactive T cells on the basis of their proliferative response in vitro may be beneficial for the recipient, less time consuming than T-cell cloning and still reduce the extent of GvHD.
Similar content being viewed by others
References
Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2002; 29: 639–646.
Ferrara JL, Cooke KR, Pan L, Krenger W . The immunopathophysiology of acute graft-versus-host-disease. Stem Cells 1996; 14: 473–489.
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.
Barnes DW, Corp MJ, Loutit JF, Neal FE . Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. BMJ 1956; 32: 626–627.
Martin PJ . Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med 1993; 178: 703–712.
Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383–387.
Simpson D . Drug therapy for acute graft-versus-host disease prophylaxis. J Hematother Stem Cell Res 2000; 9: 317–325.
Zeiser R, Marks R, Bertz H, Finke J . Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol 2004; 83: 551–565.
Martin PJ, Hansen JA, Torok-Storb B, Moretti L, Press O, Storb R et al. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1988; 3: 437–444.
Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR . Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971–1979.
Cavazzana-Calvo M, Andre-Schmutz I, Hacein-Bey-Abina S, Bensoussan D, Le Deist F, Fischer A . Improving immune reconstitution while preventing graft-versus-host disease in allogeneic stem cell transplantation. Semin Hematol 2002; 39: 32–40.
Cavazzana-Calvo M, Fromont M, Le Deist F, Lusardi M, Coulombel L, Derocq JM et al. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 1990; 50: 1–7.
Fehse B, Frerk O, Goldman M, Bulduk M, Zander AR . Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol 2000; 109: 644–651.
Hartwig UF, Robbers M, Wickenhauser C, Huber C . Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood 2002; 99: 3041–3049.
Chen BJ, Cui X, Liu C, Chao NJ . Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 2002; 99: 3083–3088.
Cohen JL, Boyer O, Salomon B, Onclercq R, Charlotte F, Bruel S et al. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 1997; 89: 4636–4645.
Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144–1150.
Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S . Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389–399.
Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198–2203.
van der Harst D, Goulmy E, Falkenburg JH, Kooij-Winkelaar YM, van Luxemburg-Heijs SA, Goselink HM et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994; 83: 1060–1066.
Lyons AB . Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000; 243: 147–154.
Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA . Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001; 166: 973–981.
Maury S, Salomon B, Klatzmann D, Cohen JL . Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice. Blood 2001; 98: 3156–3158.
Godfrey WR, Krampf MR, Taylor PA, Blazar BR . Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 2004; 103: 1158–1165.
Parr L . Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumour. Br J Cancer 1972; 26: 174–177.
Fields PE, Finch RJ, Gray GS, Zollner R, Thomas JL, Sturmhoefel K et al. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol 1998; 161: 5268–5275.
Beck C, Schreiber K, Schreiber H, Rowley DA . C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum. Eur J Immunol 2003; 33: 19–28.
Seung LP, Rowley DA, Dubey P, Schreiber H . Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 1995; 92: 6254–6258.
Hestdal K, Ruscetti FW, Ihle JN, Jacobsen SE, Dubois CM, Kopp WC et al. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol 1991; 147: 22–28.
Storek J . B-cell immunity after allogeneic hematopoietic cell transplantation. Cytotherapy 2002; 4: 423–424.
Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A . B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant 1993; 12: 387–398.
Glass B, Uharek L, Zeis M, Dreger P, Loffler H, Steinmann J et al. Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect. Blood 1997; 90: 1694–1700.
Billiau AD, Fevery S, Rutgeerts O, Landuyt W, Waer M . Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. Blood 2002; 100: 1894–1902.
Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE . RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68: 869–877.
Gratwohl A, Brand R, Apperley J, Biezen Av A, Bandini G, Devergie A et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100: 3877–3886.
Kolb HJ, Schmid C, Barrett AJ, Schendel DJ . Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767–776.
Maury S, Mary JY, Rabian C, Schwarzinger M, Toubert A, Scieux C et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol 2001; 115: 630–641.
Storek J, Espino G, Dawson MA, Storer B, Flowers ME, Maloney DG . Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 2000; 96: 3290–3293.
Oettel KR, Wesly OH, Albertini MR, Hank JA, Iliopolis O, Sosman JA et al. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1− cells from the same patient. Blood 1994; 83: 3390–3402.
Singh S, Ross SR, Acena M, Rowley DA, Schreiber H . Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 1992; 175: 139–146.
Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF et al. Increasing tumor antigen expression overcomes ‘ignorance’ to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 17: 737–747.
Blazar BR, Lees CJ, Martin PJ, Noelle RJ, Kwon B, Murphy W et al. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J Immunol 2000; 165: 4901–4909.
Falkenburg JH, Wafelman AR, Joosten P, Smit WM, van Bergen CA, Bongaerts R et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201–1208.
Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742–2747.
Acknowledgements
We thank Dr Christoph Schulte, Department of Pathology for help with cell sorting, Professor P Saftig, Department for Biochemistry for providing lab space and unlimited support of the project, S Gehrmann and T Steffen for technical assistance and Mr Deger for excellent animal care. We are indebted to the DJCLS, Munich, Germany and Deutsche Krebshilfe-Stiftung, Bonn, Germany for financial support. This work is dedicated to Janet and Donald Rowley in gratitude and friendship. This work was supported by Grant R01/07 of the DJCLS, German José Carreras Leukemia Foundation, Munich, Germany and Grant 10-2114, Deutsche Krebshilfe-Stiftung, Bonn, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pachnio, A., Dietrich, S., Klapper, W. et al. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation. Bone Marrow Transplant 38, 157–167 (2006). https://doi.org/10.1038/sj.bmt.1705411
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705411
- Springer Nature Limited